CompletedPhase 1NCT00082784

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Studying Marginal zone lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Steven Grant
Moffitt Cancer Center
Intervention: Bortezomib(drug)
Enrollment: 93 enrolled
Eligibility: 18 years · All sexes
Timeline: 2004 – 2014

Study locations (5)

Moffitt Cancer Center, Tampa, Florida, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00082784 on ClinicalTrials.gov

Other trials for Marginal zone lymphoma

Additional recruiting or active studies for the same condition.

RECRUITINGNCT05700149
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)

See all trials for Marginal zone lymphoma →

← Back to all trials